03:57 AM EST, 02/11/2025 (MT Newswires) -- Novartis ( NVS ) and Blackstone's (BX) Blackstone Life Sciences said Tuesday they have signed a deal for Novartis ( NVS ) to acquire Anthos Therapeutics for up to $3.1 billion.

Novartis ( NVS ) will make an upfront payment of $925 million at closing, and potential additional payments of up to $2.15 billion based on the achievement of regulatory and sales milestones.

Blackstone Life Sciences and Novartis ( NVS ) launched Anthos in 2019 with exclusive international rights from Novartis ( NVS ) to develop, produce and commercialize abelacimab, intended to prevent stroke and systemic embolism in patients with atrial fibrillation and to prevent blood clots recurrence in cancer patients. Abelacimab is currently in phase 3 development.

The transaction is expected to close in H1 this year, the companies said.